WallStreetZenWallStreetZen

NASDAQ: AVTE
Aerovate Therapeutics Inc Stock

$22.25+0.39 (+1.78%)
Updated Jun 11, 2024
AVTE Price
$22.25
Fair Value Price
$0.87
Market Cap
$640.99M
52 Week Low
$9.41
52 Week High
$32.42
P/E
-7.32x
P/B
7.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.19M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$69M
Beta
1.49
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AVTE Overview

Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing drugs to treat rare cardiopulmonary diseases. Pulmonary Arterial Hypertension is a rare progressive and often fatal cardiopulmonary disease affecting both the heart and lungs. Aerovate's lead program, AV-101, is an inhalable dry to address the underlying hyperproliferation of cells within the narrowed arteries of the lungs. Aerovate Therapeutics was incorporated in 2018 and is headquartered in Waltham, MA.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVTE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AVTE ($22.25) is overvalued by 2,467.84% relative to our estimate of its Fair Value price of $0.87 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVTE ($22.25) is not significantly undervalued (2,467.84%) relative to our estimate of its Fair Value price of $0.87 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVTE due diligence checks available for Premium users.

Be the first to know about important AVTE news, forecast changes, insider trades & much more!

AVTE News

Valuation

AVTE fair value

Fair Value of AVTE stock based on Discounted Cash Flow (DCF)
Price
$22.25
Fair Value
$0.87
Overvalued by
2,467.84%
AVTE ($22.25) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVTE ($22.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AVTE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-7.32x
Industry
-3.83x
Market
29.53x

AVTE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.05x
Industry
6.25x
AVTE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AVTE's financial health

Profit margin

Revenue
$0.0
Net Income
-$23.2M
Profit Margin
0%
AVTE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$106.8M
Liabilities
$15.9M
Debt to equity
0.18
AVTE's short-term assets ($103.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVTE's short-term assets ($103.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVTE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$23.7M
Investing
$8.8M
Financing
$471.0k
AVTE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AVTE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AVTE$640.99M+1.78%-7.32x7.05x
LYEL$639.90M+6.36%-2.79x1.06x
SAGE$637.93M-2.75%-1.26x0.90x
MLYS$644.93M-3.78%-5.88x1.97x
PHAT$645.64M+2.70%-2.47x-4.35x

Aerovate Therapeutics Stock FAQ

What is Aerovate Therapeutics's quote symbol?

(NASDAQ: AVTE) Aerovate Therapeutics trades on the NASDAQ under the ticker symbol AVTE. Aerovate Therapeutics stock quotes can also be displayed as NASDAQ: AVTE.

If you're new to stock investing, here's how to buy Aerovate Therapeutics stock.

What is the 52 week high and low for Aerovate Therapeutics (NASDAQ: AVTE)?

(NASDAQ: AVTE) Aerovate Therapeutics's 52-week high was $32.42, and its 52-week low was $9.41. It is currently -31.36% from its 52-week high and 136.45% from its 52-week low.

How much is Aerovate Therapeutics stock worth today?

(NASDAQ: AVTE) Aerovate Therapeutics currently has 28,808,334 outstanding shares. With Aerovate Therapeutics stock trading at $22.25 per share, the total value of Aerovate Therapeutics stock (market capitalization) is $640.99M.

Aerovate Therapeutics stock was originally listed at a price of $22.83 in Jun 30, 2021. If you had invested in Aerovate Therapeutics stock at $22.83, your return over the last 2 years would have been -2.54%, for an annualized return of -1.28% (not including any dividends or dividend reinvestments).

How much is Aerovate Therapeutics's stock price per share?

(NASDAQ: AVTE) Aerovate Therapeutics stock price per share is $22.25 today (as of Jun 11, 2024).

What is Aerovate Therapeutics's Market Cap?

(NASDAQ: AVTE) Aerovate Therapeutics's market cap is $640.99M, as of Jun 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aerovate Therapeutics's market cap is calculated by multiplying AVTE's current stock price of $22.25 by AVTE's total outstanding shares of 28,808,334.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.